How much does Blincyto (blinatumomab) cost?

The cost of a Blincyto (blinatumomab) vial is approximately $5,427 per 35 microgram (mcg) single-dose vial for injection. The overall cost for your therapy will also depend upon the length of treatment. Most people do not pay out-of-pocket for the full price of Blincyto.

Learn More: Blincyto Prices, Coupons and Patient Assistance Programs

This Blincyto price is based on using the Drugs.com discount card. The cash price can vary based upon your insurance, your clinic or hospital cost, and any administration fees for the injection.

This drug is usually given by a health care provider in a clinic or hospital and is not found in a traditional pharmacy. The cost for this medicine may be covered by your insurance but you may have a deductible, copay or coinsurance.

Can I get help paying for Blincyto?

Commercial Insurance

Blincyto is manufactured by Amgen, who may be able to provide financial assistance to help cover some or all of the cost of Blincyto through their Amgen Support Plus program. Contact them to learn more about the options and to determine if you are eligible.

If you have private or commercial insurance (that you get from your employer or buy directly from a health insurance company), you may qualify for the Amgen Support Plus Co-pay program which may be able to provide funds to help you pay your deductible, copay, or coinsurance. For example:

• Up to a $0 out-of-pocket for treatment doses
• Can be applied to deductible, co-insurance, and co-payment
• No income eligibility requirement

You can enroll online at AmgenSupportPlus.com/copay or over the phone by calling (866) 264-2778

Medicare, other government insurance or no insurance

If you have government insurance like Medicare, Amgen may be able to refer you to nonprofit patient assistance programs to help you afford your copays.

If you have no insurance, or are underinsured, contact Amgen to determine if you qualify for Amgen medicines at no cost to you through the Amgen Safety Net Foundation patient assistance program.

To learn more about nonprofit assistance or the Safet Net Foundation call Amgen Support Plus at 1-866-264-2778, Monday to Friday 9:00 am to 8:00 pm ET.

Related Questions

• What are monoclonal antibodies?
• Is Blincyto (blinatumomab) chemotherapy?
• How is Blincyto taken / administered?

What is Blincyto used for?

Blincyto is used to treat Acute Lymphoblastic Leukemia (ALL), a type of cancer of the blood where a kind of white blood cell starts growing out of control.

Blincyto is a prescription medicine approoved to treat adults and children with:

• CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) that has come back (relapsed) or did not respond to previous treatments (refractory).
• CD19 positive B-cell precursor ALL in in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. MRD is when only a small number of cancer cells remain in the body.

Blincyto is considered an immunotherapy anticancer treatment but it is not a traditional chemotherapy medicine. Immunotherapy uses the body’s own immune system to better target cancer cells.

Blincyto is classified as a bispecific CD19-directed CD3 T-cell engager (or BiTE antibody). Blincyto is a monoclonal antibody that is considered a targeted therapy anticancer drug.

How is Blincyto given?

Blincyto is given by a continuous intravenous (IV) infusion into your vein by a special pump. Your healthcare provider will determine how much medicine to give you and how often you will receive treatment.

You may need to receive Blincyto in a hospital or clinic, especially when first starting treatment, so your healthcare provider can check you for side effects.

This is not all the information you need to know about Blincyto (blinatumomab) for safe and effective use and does not take the place of your healthcare provider's directions. Review the full Blincyto patient information discuss this information and any questions you have with your doctor or other health care provider.